Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction
Institut d'Investigacions Biomèdiques August Pi i Sunyer
304 participants
Jan 18, 2023
INTERVENTIONAL
Conditions
Summary
Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.
Eligibility
Inclusion Criteria4
- Singleton pregnancies
- Non-malformed fetus
- Pregnancies with fetal growth restriction
- weeks of gestation
Exclusion Criteria4
- Chromosomal or structural abnormalities diagnosed during pregnancy or in the neonatal period
- Critical Doppler study suggesting the need for delivery within the next 14 days at the time of diagnosis: reverse end-diastolic velocity in the umbilical artery or ductus venosus pulsatility \>95th centile
- Maternal mental or psychiatric disorders
- Maternal allergy to cow's milk protein
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
Product with the same physical appearance and taste as the main intervention but without therapeutic effect
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05038462